Compounding Pharmacy EBITDA Valuation Multiples: What Buyers Are Paying in 2024
PCAB accreditation, clean regulatory history, and diversified prescriber bases drive multiples from 3.5x to 6x EBITDA in today's specialty pharmacy M&A market.
Compounding pharmacies trade at 3.5x to 6x EBITDA in the lower middle market, reflecting their high regulatory barriers, sticky prescriber relationships, and growing demand across HRT, veterinary, and pain management niches. Valuation spread is wide because regulatory risk, prescriber concentration, and cleanroom compliance status dramatically separate premium assets from distressed ones. PCAB-accredited sterile compounders with diversified physician referral networks and documented SOPs consistently command top-tier multiples, while businesses with FDA 483 observations or owner-dependent revenue face meaningful discounts. SBA 7(a) financing is widely available for qualified buyers, supporting deal structures that include seller notes and earnouts tied to prescriber retention milestones.
Compounding Pharmacy EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or High-Risk | $200K–$500K | 3.5x–4.0x | Regulatory citations, owner-dependent prescriber relationships, non-compliant cleanrooms, or heavy revenue concentration in one or two physicians. |
| Average Quality | $500K–$800K | 4.0x–4.75x | Stable operations with mixed sterile and non-sterile volume, moderate prescriber diversification, and no major regulatory flags but limited accreditation. |
| Above Average | $800K–$1.2M | 4.75x–5.5x | PCAB accredited, USP 797/800-compliant facility, recurring chronic-condition patient base, and documented SOPs with cross-trained pharmacist staff. |
| Premium Asset | $1.2M+ | 5.5x–6.0x | Sterile compounding focus, diversified multi-specialty prescriber base, proprietary HRT or veterinary formulations, and clean multi-year regulatory history. |
What Drives Compounding Pharmacy Multiples
PCAB Accreditation and Regulatory History
High Positive impactPCAB-accredited pharmacies with zero FDA 483 observations or state board sanctions command 0.5x–1.0x premium; any outstanding consent orders can eliminate qualified buyers.
Prescriber Concentration Risk
High Negative impactReferral bases where one or two physicians exceed 30% of revenue create significant earnout requirements and can reduce multiples by 0.5x–1.5x.
Sterile vs. Non-Sterile Revenue Mix
Moderate Positive impactSterile compounding commands higher margins and strategic value; buyers pay premiums for ISO-classified cleanrooms with current third-party certification and HVAC validation.
Proprietary Niche Formulations
Moderate Positive impactDefensible specialization in HRT, veterinary, or pediatric compounding creates recurring revenue and limits retail pharmacy competition, supporting upper-tier multiples.
Pharmacist-in-Charge Succession Plan
High Positive impactBusinesses with a licensed backup pharmacist ready to serve as PIC post-close transact faster and at higher multiples than owner-only operations with no succession path.
Recent Market Trends
PE-backed specialty pharmacy platforms have increased acquisition activity in sterile compounding, compressing cap rates at the premium tier. Rising USP 800 compliance costs are pressuring smaller non-sterile operators to sell before required capital upgrades erode proceeds. SBA 7(a) lending remains active for licensed-pharmacist buyers, with lenders increasingly comfortable with compounding pharmacy cash flows when PCAB accreditation and clean regulatory histories are documented. Earnout structures tied to 12-month prescriber retention are now standard in deals where the selling pharmacist-owner controls key referral relationships.
Sample Compounding Pharmacy Transactions
PCAB-accredited sterile compounder serving HRT and pain management physicians across three states; diversified 40-prescriber referral base with auto-refill program.
$1.1M
EBITDA
5.6x
Multiple
$6.16M
Price
Non-sterile veterinary and pediatric compounder; strong SOP documentation and recurring patient base but no PCAB accreditation and single-state licensure.
$620K
EBITDA
4.4x
Multiple
$2.73M
Price
Sterile compounding pharmacy with FDA 483 observation resolved prior to close; earnout tied to 18-month prescriber retention and seller equity rollover as PIC.
$780K
EBITDA
4.1x
Multiple
$3.20M
Price
EBITDA Valuation Estimator
Get your Compounding Pharmacy business value range instantly
Industry: Compounding Pharmacy · Multiples based on 4.0x–4.75x (Average Quality)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
What EBITDA multiple should I expect when selling my compounding pharmacy?
Most compounding pharmacies sell at 3.5x–6x EBITDA. PCAB accreditation, sterile capabilities, and a diversified prescriber base push values toward the upper end of that range.
How does prescriber concentration affect my compounding pharmacy's sale price?
If one or two physicians drive more than 30% of revenue, buyers will discount the multiple and require earnouts tied to post-close prescriber retention, sometimes reducing proceeds significantly.
Can I buy a compounding pharmacy with an SBA loan?
Yes. SBA 7(a) loans are widely used for compounding pharmacy acquisitions. The buyer or a key employee must hold pharmacist-in-charge licensure to satisfy lender and state board requirements.
Does an outstanding FDA 483 observation kill a compounding pharmacy deal?
Not always, but it narrows the buyer pool considerably. Resolved observations with documented corrective actions allow deals to proceed, often with representations and warranties insurance and price adjustments.
More Compounding Pharmacy Guides
Find Compounding Pharmacy businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required